Treatment | Day of treatment or re-infestation | |||||||
---|---|---|---|---|---|---|---|---|
0 | 14 | 28 | 42 | 58 | 76 | 90 | ||
Placebo | Range | 17–31 | 4–18 | 7–24 | 9–28 | 9–30 | 8–26 | 7–23 |
A. mean | 23.5 | 11.6 | 15.1 | 15.8 | 19.9 | 16.1 | 17.5 | |
G. mean1 | 23.1a | 10.6a | 13.6a | 14.6a | 18.8a | 15.0a | 16.6a | |
Sarolaner | Range | 6–28 | 2–15 | 7–20 | 9–34 | 6–18 | 3–22 | 10–24 |
A. mean | 16.8 | 9.3 | 12.0 | 17.3 | 12.8 | 14.4 | 16.1 | |
Efficacy (%) | 28.7 | 20.4 | 20.7 | 0.0 | 35.8 | 10.9 | 7.9 | |
G. mean1 | 15.4a,b | 7.8a | 11.4a | 15.9a | 12.3a | 12.7a | 15.5a | |
Efficacy (%) | 33.2 | 26.3 | 16.1 | 0.0 | 34.7 | 15.3 | 6.7 | |
P-value vs placebo | 0.1338 | 0.2817 | 0.5240 | 0.7543 | 0.1177 | 0.5432 | 0.7973 | |
Fluralaner | Range | 2–30 | 2–17 | 8–18 | 5–26 | 12–27 | 7–19 | 11–30 |
A. mean | 16.3 | 8.1 | 14.1 | 19.5 | 16.6 | 13.3 | 17.0 | |
Efficacy (%) | 30.9 | 30.1 | 6.6 | 0.0 | 16.4 | 17.8 | 2.9 | |
G. mean1 | 12.7b | 7.0a | 13.6a | 17.7a | 16.1a | 12.7a | 16.2a | |
Efficacy (%) | 45.0 | 33.8 | 0.4 | 0.0 | 14.0 | 15.7 | 2.6 | |
P-value vs placebo | 0.0218 | 0.1317 | 0.9883 | 0.4619 | 0.5580 | 0.5149 | 0.9203 | |
P-value vs sarolaner | 0.5337 | 0.7457 | 0.5867 | 0.7321 | 0.3792 | 0.9889 | 0.8883 |